Drugs / vMCO-I
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04919473 | Oct 2019 → Feb 2020 | retinitis pigmentosa | Nanoscope Therapeutics Inc. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vMCO-I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04919473 ↗ |
| Known as | Multi-Characteristic Opsin I | “The purpose of the study is to evaluate the safety and tolerability of a single intravitreal injection of virally-carried Multi-Characteristic Opsin I (vMCO-I)” NCT04919473 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “The vMCO-I is an adeno-associated virus serotype 2-based vector carried multi-characteristic opsin (MCO) gene expression cassette” NCT04919473 ↗ |
| Route | Intravitreal | “a single intravitreal injection” NCT04919473 ↗ |